Polio
Conditions
Interventions
Group1 (sIPV+bOPV+bOPV):Subjects were vaccinated with 1 dose of Sabin-IPV and 2 doses of bOPV at their age of 2/3/4 months old, respectively.One month interval between each dose, complete basic immuni
Group2 (sIPV+sIPV+bOPV):Subjects were vaccinated with 2 doses of Sabin-IPV and 1 dose of bOPV at their age of 2/3/4 months old, respectively.Complete basic immunization.
Group3 (sIPV+sIPV+sIPV):Subjects were vaccinated with 3 doses of Sabin-IPV at their age of 2/3/4 months old, respectively.Complete basic immunization.
Sponsors
Inner Mongolia Autonomous Region Center for Diseases Prevention and Control
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects aged 2 months old at the date of recruitment; 2.with informed consent signed by parent(s) or guardians; 3.parent(s) or guardians are able to attend all planned clinical appointments and obey and follow all study instructions; 4.Subjects have never been vaccinated with rotavirus or DPT vaccine; 5.subjects did not receive any vaccination within 14 days; 6.axillary temperature <= 37.0 degrees C.
Exclusion criteria
Exclusion criteria: 1.With a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness; 2.Allergic to any ingredient of vaccine or with allergy history to any vaccine; 3.Subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone); 4.Administration of immunoglobulins within 30 days prior to this study; 5.Acute febrile disease(temperature >= 37.0 degrees C) or infectious disease; 6.With a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause contraindications for subcutaneous injection; 7.With any serious chronic illness, acute infectious diseases, or respiratory diseases; 8.Suffering from severe cardiovascular disease (pulmonary heart disease, pulmonary edema, high blood pressure can not be controlled to the normal range by drugs), liver and kidney disease, diabetes with complications; 9.With any kind of infectious, purulent, or allergic skin diseases; 10.With any other factor that makes the investigator determines the subject is unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody positive rate;Seroconversion rate;Geometric Mean Titres (GMT);Geometric Mean Titres (GMT); | — |
Secondary
| Measure | Time frame |
|---|---|
| the occurrence of adverse events; | — |
Countries
China
Contacts
Public ContactShaohong Yan
Outcome results
None listed